Instruction for use: Eglonil

Packing: tablets, capsules

Active substance: Sulpiride

ATX

N05AL01 Sulpiride

Pharmacological group:

Neroleptics

Composition and release form

Capsules 1 caps.

Sulpiride 50 mg

in a blister of 10 pcs .; in the box 3 blisters.

Tablets 1 table.

Sulpiride 200 mg

12 pieces in the blister; in the box 1 blister.

Solution for intramuscular injection 1 amp.

Sulpiride 100 mg

6 ampoules in the blister; in the box 1 blister.

Solution for oral administration (preferably for children) 0.5% 100 ml

Sulpiride 500 mg

(1 tsp lodka 5 ml - 25 mg and 20 drops - 5 mg)

in glass bottles of 200 ml.

Pharmachologic effect

Pharmacological action - antipsychotic.

Blocks dopamine receptors.

Pharmacodynamics

In small doses, acting at the level of the central dopaminergic receptors, exerts a disinhibiting effect. In doses over 600 mg / day reduces the productive symptoms (actually the antipsychotic effect).

Pharmacokinetics

After parenteral administration, 100 mg of Cmax (2.2 mg / L) is determined after 30 minutes, after oral administration of 200 mg (0.73 mg / l) after 4.5 hours. Bioavailability after oral administration is 25-35% (may vary considerably among the individual patients). Easily penetrates into all organs, especially rapidly in the liver and kidneys, more slowly in the brain tissue (the main amount is concentrated in the pituitary gland). Binding to plasma proteins - 40%. T1 / 2 is about 7 hours. Practically not exposed to biotransformation. Total Cl: 126 ml / min. Excretion is mainly carried out by the kidneys (92% of the administered dose) by glomerular filtration and secretion; A small part (about 1% of the daily dose) is excreted in breast milk.

Indications of the preparation Eglonil

Acute and chronic psychoses (retardation, delirium, confusion, agrammatism, abulia), schizophrenia; neurotic states, accompanied by retardation; psychosomatic symptoms (especially with peptic ulcer of the stomach and duodenum and hemorrhagic rectocolitis).

Contraindications

Hypersensitivity, suspicion of pheochromocytoma.

Application in pregnancy and lactation

With prolonged use of high doses (over 200 mg / day), newborns sometimes had an extrapyramidal syndrome. Therefore, when it is necessary to carry out treatment in pregnant and lactating women, it is recommended to lower the dose and reduce the duration of treatment.

Side effects

With prolonged use in high doses, sometimes inhibition, drowsiness, hyperprolactinaemia, amenorrhea, galactorrhea, gynecomastia, impotence, frigidity, weight gain, early (spastic, torticollis, oculomotor disorders, spasm of the masticatory musculature) and late dyskinesias, extrapyramidal disorders, orthostatic hypotension , malignant neuroleptic syndrome (hyperthermia).

Interaction

Weakens the effect of levodopa, increases the severity of lowering blood pressure on the background of antihypertensive drugs; is incompatible with alcohol and other drugs that depress the central nervous system (mutual enhancement of sedative properties).

Dosing and Administration

Psychoses: IM - 200-800 mg / day for 2 weeks; inside - with negative symptoms - 200-600 mg / day, with productive symptoms - at 800-1600 mg / day, with motor retardation and psychosomatic disorders - 100-200 mg / day, with peptic ulcer of the stomach and duodenum - 150 mg / day for 4-6 weeks. Children (preferably in the form of a solution for oral administration) - 5-10 mg / kg / day (1 tea - 25 mg, 4 drops - 1 mg).

Precautionary measures

Be wary appoint patients with kidney failure, epilepsy, Parkinsonism, the elderly and the newborn; during work drivers of vehicles and people whose profession is associated with increased concentration of attention.

Storage conditions for Eglonil

At a temperature not exceeding 30 ° C.

Keep out of the reach of children.

Shelf life of Eglonil

3 years.

Do not use after the expiry date printed on the package.